Grant of Interim Extension of the Term of U.S. Patent No. 6,406,699; ECI® (ELIAS Cancer Immunotherapy), 62713-62714 [2020-21969]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 85, No. 193 / Monday, October 5, 2020 / Notices
Atlantic Bluefish Fishery Management
Plan in late 2017. A notice of intent to
develop an environmental impact
statement for this action was published
in June 2018. However, following a
second round of scoping meetings in
February and March 2020, it has been
determined that the range of proposed
alternatives included in this amendment
are not expected to have significant
impacts on the fishery or affected
environment. Therefore, NMFS is
withdrawing the notice of intent and
will continue development of an
environmental assessment instead.
FOR FURTHER INFORMATION CONTACT:
Cynthia Ferrio, Fishery Policy Analyst,
(978) 281–9180.
SUPPLEMENTARY INFORMATION: In
December 2017, the Council initiated a
comprehensive amendment to the
Bluefish Fishery Management Plan
(FMP) to review and update the goals
and objectives of this FMP, as well as
reevaluate quota allocation and transfer
provisions between sectors and states,
in light of changing fishery conditions
and stakeholder priorities. The Council
published a notice of intent to develop
an environmental impact statement for
this amendment in accordance with the
National Environmental Policy Act to
analyze the impacts of any proposed
management measures (83 FR 26267;
June 6, 2018), and held a series of
scoping hearings with the Atlantic
States Marine Fisheries Commission’s
Bluefish Board in June and July of 2018.
Following this round of scoping,
development on the amendment was
put on hold until the results of the
August 2019 operational stock
assessment were available that
incorporated revised Marine
Recreational Information Program data
into its model.
The 2019 assessment determined that
the bluefish stock is now overfished
although overfishing is not occurring,
and at its December 2019 meeting, the
Council decided to add the rebuilding
plan to Amendment 7. The Council
must develop and implement a
rebuilding plan within 2 years of
notification that a stock is overfished, by
the end of November 2021. Following a
second round of scoping hearings in
February and March 2020, the Council
and NMFS have determined that the
range of proposed alternatives included
in this amendment are not expected to
have significant impacts on the fishery
or affected environment and that an
environmental assessment will be
developed. Therefore, this notice
announces the Council’s withdrawal of
the Notice of Intent to Prepare an
Environmental Impact Statement for
VerDate Sep<11>2014
23:42 Oct 02, 2020
Jkt 253001
Amendment 7 to the Bluefish FMP.
Development of the amendment will
continue with an environmental
assessment instead.
Authority: 16 U.S.C. 1801 et seq.
Dated: September 29, 2020.
Jennifer M. Wallace,
Acting Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2020–21877 Filed 10–2–20; 8:45 am]
BILLING CODE 3510–22–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2020–0047]
Grant of Interim Extension of the Term
of U.S. Patent No. 7,259,184;
Vernakalant Hydrochloride
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 7,259,184
(‘184 patent).
FOR FURTHER INFORMATION CONTACT: Raul
Tamayo, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–7728 or by email
to raul.tamayo@uspto.gov.
SUPPLEMENTARY INFORMATION: 35 U.S.C.
156 generally provides that the term of
a patent may be extended for a period
of up to five years, if the patent claims
a product, or a method of making or
using a product, that has been subject to
certain defined regulatory review. 35
U.S.C. 156(d)(5) generally provides that
the term of such a patent may be
extended for no more than five interim
periods of up to one year each, if the
approval phase of the regulatory review
period is reasonably expected to extend
beyond the expiration date of the patent.
On July 14, 2020, Correvio
International Sa`rl, the owner of record
of the ‘184 patent, timely filed an
application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
the ‘184 patent. The ‘184 patent claims
a method of using the product
vernakalant hydrochloride. The
application for interim patent term
extension indicates that New Drug
Application No. 22–034 for vernakalant
hydrochloride was submitted to the
Food and Drug Administration (FDA) on
December 19, 2006, and that the FDA’s
review thereof is ongoing.
SUMMARY:
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
62713
Review of the interim patent term
extension application indicates that,
except for permission to market or use
the product commercially, the ‘184
patent would be eligible for an
extension of the patent term under 35
U.S.C. 156. Because it appears the
approval phase of the regulatory review
period will continue beyond the original
expiration date of the patent, i.e.,
October 6, 2020, interim extension of
the ‘184 patent’s term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
7,259,184 is granted for a period of one
year from the original expiration date of
the ‘184 patent.
Robert Bahr,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
[FR Doc. 2020–21968 Filed 10–2–20; 8:45 am]
BILLING CODE 3510–1630–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2020–0049]
Grant of Interim Extension of the Term
of U.S. Patent No. 6,406,699; ECI®
(ELIAS Cancer Immunotherapy)
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 6,406,699
(’699 patent).
FOR FURTHER INFORMATION CONTACT: Raul
Tamayo, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–7728 or by email
to raul.tamayo@uspto.gov.
SUPPLEMENTARY INFORMATION: 35 U.S.C.
156 generally provides that the term of
a patent may be extended for a period
of up to five years, if the patent claims
a product, or a method of making or
using a product, that has been subject to
certain defined regulatory review. 35
U.S.C. 156(d)(5) generally provides that
the term of such a patent may be
extended for no more than five interim
periods of up to one year each, if the
approval phase of the regulatory review
period is reasonably expected to extend
beyond the expiration date of the patent.
On August 17, 2020, TVAX Biomedical
I, LLC, the owner of record of the ’699
patent, timely filed an application under
SUMMARY:
E:\FR\FM\05OCN1.SGM
05OCN1
62714
Federal Register / Vol. 85, No. 193 / Monday, October 5, 2020 / Notices
35 U.S.C. 156(d)(5) for a second interim
extension of the term of the ’699 patent.
The ’699 patent claims a method of
using a veterinary biological product in
the cancer immunotherapy treatment
known by the tradename ECI® (ELIAS
Cancer Immunotherapy). The
application for interim patent term
extension indicates that an application
for a license for the veterinary biological
product was submitted under the VirusSerum-Toxin Act and is currently
undergoing regulatory review by the
United States Department of
Agriculture, Center for Veterinary
Biologics.
Review of the interim patent term
extension application indicates that,
except for permission to market or use
the product commercially, the ’699
patent would be eligible for an
extension of the patent term under 35
U.S.C. 156. Because it appears the
approval phase of the regulatory review
period will continue beyond the
extended expiration date of the ’699
patent, i.e., October 5, 2020, further
interim extension of the patent term
under 35 U.S.C. 156(d)(5) is appropriate.
A second interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 6,406,699 is granted for a
period of one year from the extended
expiration date of the ’699 patent.
[Docket No. PTO–P–2020–0048]
35 U.S.C.
156 generally provides that the term of
a patent may be extended for a period
of up to five years, if the patent claims
a product, or a method of making or
using a product, that has been subject to
certain defined regulatory review. 35
U.S.C. 156(d)(5) generally provides that
the term of such a patent may be
extended for no more than five interim
periods of up to one year each, if the
approval phase of the regulatory review
period is reasonably expected to extend
beyond the expiration date of the patent.
On July 14, 2020, Correvio
International Sa`rl, the owner of record
of the ‘879 patent, timely filed an
application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
the ‘879 patent. The ‘879 patent claims
a method of using the product
vernakalant hydrochloride. The
application for interim patent term
extension indicates that New Drug
Application No. 22–034 for vernakalant
hydrochloride was submitted to the
Food and Drug Administration (FDA) on
December 19, 2006, and that the FDA’s
review thereof is ongoing.
Review of the interim patent term
extension application indicates that,
except for permission to market or use
the product commercially, the ‘879
patent would be eligible for an
extension of the patent term under 35
U.S.C. 156. Because it appears the
approval phase of the regulatory review
period will continue beyond the original
expiration date of the patent, i.e.,
October 6, 2020, interim extension of
the ‘879 patent’s term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
7,5242,879 is granted for a period of one
year from the original expiration date of
the ‘879 patent.
Grant of Interim Extension of the Term
of U.S. Patent No. 7,524,879;
Vernakalant Hydrochloride
Robert Bahr,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
Robert Bahr,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
[FR Doc. 2020–21969 Filed 10–2–20; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[FR Doc. 2020–21966 Filed 10–2–20; 8:45 am]
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
jbell on DSKJLSW7X2PROD with NOTICES
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 7,524,879
(‘879 patent).
FOR FURTHER INFORMATION CONTACT: Raul
Tamayo, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–7728 or by email
to raul.tamayo@uspto.gov.
SUMMARY:
VerDate Sep<11>2014
23:42 Oct 02, 2020
Jkt 253001
SUPPLEMENTARY INFORMATION:
Patent and Trademark Office
[Docket No. PTO–P–2020–0046]
Grant of Interim Extension of the Term
of U.S. Patent No. 7,057,053;
Vernakalant Hydrochloride
United States Patent and
Trademark Office, Department of
Commerce.
AGENCY:
PO 00000
Frm 00025
Fmt 4703
Sfmt 9990
Notice of interim patent term
extension.
ACTION:
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 7,057,053
(‘053 patent).
SUMMARY:
Raul
Tamayo, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–7728 or by email
to raul.tamayo@uspto.gov.
FOR FURTHER INFORMATION CONTACT:
35 U.S.C.
156 generally provides that the term of
a patent may be extended for a period
of up to five years, if the patent claims
a product, or a method of making or
using a product, that has been subject to
certain defined regulatory review. 35
U.S.C. 156(d)(5) generally provides that
the term of such a patent may be
extended for no more than five interim
periods of up to one year each, if the
approval phase of the regulatory review
period is reasonably expected to extend
beyond the expiration date of the patent.
On July 14, 2020, Correvio
International Sa`rl, the owner of record
of the ‘053 patent, timely filed an
application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
the ‘053 patent. The ‘053 patent claims
the product vernakalant hydrochloride.
The application for interim patent term
extension indicates that New Drug
Application No. 22–034 for vernakalant
hydrochloride was submitted to the
Food and Drug Administration (FDA) on
December 19, 2006, and that the FDA’s
review thereof is ongoing.
Review of the interim patent term
extension application indicates that,
except for permission to market or use
the product commercially, the ‘053
patent would be eligible for an
extension of the patent term under 35
U.S.C. 156. Because it appears the
approval phase of the regulatory review
period will continue beyond the original
expiration date of the patent, i.e.,
October 16, 2020, interim extension of
the ‘053 patent’s term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
7,057,053 is granted for a period of one
year from the original expiration date of
the ‘053 patent.
SUPPLEMENTARY INFORMATION:
Robert Bahr,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
[FR Doc. 2020–21963 Filed 10–2–20; 8:45 am]
BILLING CODE 3510–16–P
E:\FR\FM\05OCN1.SGM
05OCN1
]]>Agencies
[Federal Register Volume 85, Number 193 (Monday, October 5, 2020)]
[Notices]
[Pages 62713-62714]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-21969]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2020-0049]
Grant of Interim Extension of the Term of U.S. Patent No.
6,406,699; ECI[supreg] (ELIAS Cancer Immunotherapy)
AGENCY: United States Patent and Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting a one-year interim extension of the term of U.S. Patent
No. 6,406,699 ('699 patent).
FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor,
Office of Patent Legal Administration, by telephone at 571-272-7728 or
by email to [email protected].
SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the
term of a patent may be extended for a period of up to five years, if
the patent claims a product, or a method of making or using a product,
that has been subject to certain defined regulatory review. 35 U.S.C.
156(d)(5) generally provides that the term of such a patent may be
extended for no more than five interim periods of up to one year each,
if the approval phase of the regulatory review period is reasonably
expected to extend beyond the expiration date of the patent. On August
17, 2020, TVAX Biomedical I, LLC, the owner of record of the '699
patent, timely filed an application under
[[Page 62714]]
35 U.S.C. 156(d)(5) for a second interim extension of the term of the
'699 patent. The '699 patent claims a method of using a veterinary
biological product in the cancer immunotherapy treatment known by the
tradename ECI[supreg] (ELIAS Cancer Immunotherapy). The application for
interim patent term extension indicates that an application for a
license for the veterinary biological product was submitted under the
Virus-Serum-Toxin Act and is currently undergoing regulatory review by
the United States Department of Agriculture, Center for Veterinary
Biologics.
Review of the interim patent term extension application indicates
that, except for permission to market or use the product commercially,
the '699 patent would be eligible for an extension of the patent term
under 35 U.S.C. 156. Because it appears the approval phase of the
regulatory review period will continue beyond the extended expiration
date of the '699 patent, i.e., October 5, 2020, further interim
extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.
A second interim extension under 35 U.S.C. 156(d)(5) of the term of
U.S. Patent No. 6,406,699 is granted for a period of one year from the
extended expiration date of the '699 patent.
Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent
and Trademark Office.
[FR Doc. 2020-21969 Filed 10-2-20; 8:45 am]
BILLING CODE 3510-16-P
